NCT02289196已完成1 期
A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 6
- 主要终点
- Adverse event number by treatment group as a measure of safety and tolerability
研究概览
简要总结
Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only HLA-A*02 positive patients.
The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female > or = 18 years of age;
- •Histologically proven malignancy;
- •Documented HLA-A*02 positivity, as determined by a central laboratory;
- •Disease control (Complete Response (CR), Partial Response (PR), or Stable Disease (SD)) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria or NED in the case of patients who received adjuvant chemotherapy
- •Patient with disease control or NED expectancy > or = 6 months according to investigator opinion;
- •ECOG performance status 0, 1;
- •Patients must have adequate renal and hepatic function as assessed by standard laboratory criteria;
- •Patients must have adequate haematological function:
- •Platelet count > or = 100 x 109/L;
- •White Blood Cell (WBC) count > or = 2.5 x 109/L;
- •Haemoglobin > or = 90g /L;
- •Female patients must be of non-child-bearing potential (i.e., women with functioning ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who are post-menopausal). Women of child-bearing potential must have a negative urine pregnancy test at baseline and agree to practice adequate contraception for 30 days prior to administration of investigational product, throughout the study treatment period and 30 days after completion of injections;
- •In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study;
- •Willing and able to sign a written informed consent.
排除标准
- •Prior treatment with cancer vaccines;
- •Treatment with immunotherapy (e.g., interferons, interleukins, Tumor Necrosis Factor (TNF), or biological response modifiers, such as Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) etc) within four weeks prior to the first vaccination;
- •Treatment with immunosuppressive agents (including corticosteroids) within 2 weeks prior to the first vaccination;
- •Treatment with any investigational drugs, within 4 weeks prior to the first vaccination;
- •Autoimmune or immunodeficiency disease that in the opinion of the investigator may compromise the safety of the patient in the study;
- •Any pre-existing medical condition requiring concomitant systemic corticosteroid or immunosuppressive therapy. The use of inhaled corticosteroids for Chronic Obstructive Pulmonary Disease (COPD) or topical steroids is allowed;
- •Known hepatitis B and/or C infection documented in patient files, testing not required;
- •Known HIV-positivity, testing not required;
- •Clinically significant hepatic dysfunction (Alanine amino transferase (ALT)>2.5 times normal upper limits [ULN], Aspartate Amino Transferase (AST)>2.5 times Upper Limit of Normal (ULN), bilirubin>1.5 times ULN);
- •Clinically significant renal dysfunction (serum creatinine>1.5 time ULN);
- •Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease with unstable angina or myocardial infarction within 6 months before enrolment) or uncontrolled ventricular arrhythmias at the time of enrolment in the study (atrial fibrillation or flutter is acceptable);
- •Splenectomy or splenic irradiation;
- •Any infectious condition that, in the opinion of the investigator, could compromise the patient's ability to develop an immune response;
- •Pregnant or lactating females (female patients of child-bearing potential will undertake pregnancy testing at screening and during study completion/withdrawal visits);
- •Alcohol or drug dependence;
- •Requirement of concurrent treatment with prohibited medication (investigational product, other anti-cancer treatments including chemotherapy, non-palliative radiotherapy, biological agents and immunomodulating agents, systemic immunosuppressive agents, including systemic corticosteroids);
- •The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations.
研究组 & 干预措施
Vx-006: 0,5mg
Experimental
Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
干预措施: Vx-006: 0,5mg (Drug)
Vx-006: 1mg
Experimental
Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
干预措施: Vx-006: 1mg (Drug)
Vx-006: 5mg
Experimental
Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
干预措施: Vx-006: 5mg (Drug)
Vx-006: 10mg
Experimental
Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
干预措施: Vx-006: 10mg (Drug)
结局指标
主要结局
Adverse event number by treatment group as a measure of safety and tolerability
时间窗: 18 Weeks
The following parameters of safety and tolerability will be assessed: * Physical examination and vital signs (blood pressure, pulse rate, body temperature, weight, height (only at baseline), * Electrocardiogram, * Adverse event evaluation, * Eastern Cooperative Oncology Group (ECOG) performance status, * Clinical laboratory evaluation: haematology and clinical chemistry * Collection of concomitant medication
次要结局
- Immune response evaluation by treatment group as a measure of efficacy(18 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid TumorsAdvanced Solid TumorsNCT03934359Shanghai De Novo Pharmatech Co., Ltd.19
已完成
1 期
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseSolid MalignanciesNCT02640755AstraZeneca4
已完成
1 期
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugAdvanced Solid TumorsNCT04095273Bayer56
终止
1 期
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]AdavosertibAdvanced Solid TumorsNCT05008913AstraZeneca2
已完成
1 期
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid CancerSolid TumoursNCT02093351AstraZeneca79